New genes in inflammatory bowel disease: lessons for complex diseases?

Lancet

Volumn 367, Issue 9518, 2006, Pages 1271-1284

  Gaya, Daniel R ^a   Russell, Richard K ^a   Nimmo, Elaine R ^a   Satsangi, Jack ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 5; DROSOPHILA DISC LARGE HOMOLOGUE 5 PROTEIN; GENE PRODUCT; MULTIDRUG RESISTANCE PROTEIN 1; PATTERN RECOGNITION RECEPTOR; PROTEIN IBD1; PROTEIN IBD2; PROTEIN IBD3; PROTEIN IBD5; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

CLINICAL GENETICS; DATA ANALYSIS; ENTERITIS; EVIDENCE BASED MEDICINE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENE STRUCTURE; GENETIC SUSCEPTIBILITY; HUMAN; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; PANETH CELL; PATHOGENESIS; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW;

EID: 33646020997     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68345-1     Document Type: Review

References (188)

1. Lapidus A., Bernell O., Hellers G., Persson P., and Lofberg R. Incidence of Crohn's disease in Stockholm County 1955-1989. Gut 41 (1997) 480-486
2. Tysk C., Lindberg E., Jarnerot G., and Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 29 (1988) 990-996
3. Orholm M., Binder V., Sorensen T., Rasmussen L., and Kyvik K. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 35 (2000) 1075-1081
4. Thompson N., Driscoll R., Pounder R., and Wakefield A. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 312 (1996) 95-96
5. Russell R., and Satsangi J. IBD: a family affair. Best Pract Res Clin Gastroenterol 18 (2004) 525-539
6. Ahmad T., Satsangi J., McGovern D., Bunce M., and Jewell D. Review article: the genetics of inflammatory bowel disease. Aliment Pharmacol Ther 15 (2001) 731-748
7. Halfvarson J., Bodin L., Tysk C., Lindberg E., and Jarnerot G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 124 (2003) 1767-1773
8. Monsen U., Bernell O., Johansson C., and Hellers G. Prevalence of inflammatory bowel disease among relatives of patients with Crohn's disease. Scand J Gastroenterol 26 (1991) 302-306
9. Probert C., Jayanthi V., Hughes A., Thompson J., Wicks A., and Mayberry J. Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and south Asians in Leicestershire. Gut 34 (1993) 1547-1551
10. Orholm M., Munkholm P., Langholz E., Nielsen O., Sorensen I., and Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med 324 (1991) 84-88
11. Peeters M., Nevens H., Baert F., et al. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 111 (1996) 597-603
12. Yang H., McElree C., Roth M., Shanahan F., Targan S., and Rotter J. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 34 (1993) 517-524
13. Freeman H. Familial Crohn's disease in single or multiple first-degree relatives. J Clin Gastroenterol 35 (2002) 9-13
14. Satsangi J., Grootscholten C., Holt H., and Jewell D. Clinical patterns of familial inflammatory bowel disease. Gut 38 (1996) 738-741
15. Polito J., Childs B., Mellits E., Tokayer A., Harris M., and Bayless T. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 111 (1996) 580-586
16. Farmer R., Michener W., and Mortimer E. Studies of family history among patients with inflammatory bowel disease. Clin Gastroenterology 9 (1980) 271-277
17. Hayward P., Satsangi J., and Jewell D. Inflammatory bowel disease and the X chromosome. Q J Med 89 (1996) 713-718
18. Gahl W., Brantly M., Kaiser-Kupfer M., et al. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N Engl J Med 338 (1998) 1258-1264
19. Weissenbach J. The Human Genome Project: from mapping to sequencing. Clin Chem Lab Med 36 (1998) 511-514
20. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University Baltimore MD and National Center for Biotechnology Information National Library of Medicine Bethesda MD. Online Mendelian Inheritance in Man. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM (accessed Jan 1, 2006)
21. Ahmad T., Tamboli C., Jewell D., and Colombel J. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 126 (2004) 1533-1549
22. Cavanaugh J. International collaboration provides convincing linkage replication in complex disease through analysis of a large pooled data set: Crohn disease and chromosome 16. Am J Hum Genet 68 (2001) 1165-1171
23. Parkes M., Barmada M., Satsangi J., Weeks D., Jewell D., and Duerr R. The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn disease. Am J Hum Genet 67 (2000) 1605-1610
24. Hampe J., Shaw S., Saiz R., et al. Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet 65 (1999) 1647-1655
25. Satsangi J., Welsh K., Bunce M., et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 347 (1996) 1212-1217
26. Van Heel D., Fisher S., Kirby A., Daly M., Rioux J., and Lewis C. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet 13 (2004) 763-770
27. Hugot J., Laurent-Puig P., Gower-Rousseau C., et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 379 (1996) 821-823
28. Hampe J., Cuthbert A., Croucher P., et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357 (2001) 1925-1928
29. Hugot J., Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
30. Ogura Y., Bonen D., Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
31. Ogura Y., Inohara N., Benito A., Chen F., Yamaoka S., and Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 276 (2001) 4812-4818
32. Yamazaki K., Takazoe M., Tanaka T., Kazumori T., and Nakamura Y. Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease. J Hum Genet 47 (2002) 469-472
33. Inoue N., Tamura K., Kinouchi Y., et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 123 (2002) 86-91
34. Croucher P., Mascheretti S., Hampe J., et al. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet 11 (2003) 6-16
35. Leong R. NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. Aliment Pharmacol Ther 17 (2003) 1465-1470
36. Russell R., Drummond H., Nimmo E., et al. Genotype-phenotype analysis in childhood-onset Crohn's disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis 11 (2005) 955-964
37. Helio T., Halme L., Lappalainen M., et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 52 (2003) 558-562
38. Bairead E., Harmon D., Curtis A., et al. Association of NOD2 with Crohn's disease in a homogenous Irish population. Eur J Hum Gen 11 (2003) 237-244
39. Arnott I., Nimmo E., Drummond H., et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?. Genes Immun 5 (2004) 417-425
40. Thjodleifsson B., Sigthorsson G., Cariglia N., et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives?. Gastroenterology 124 (2003) 1728-1737
41. Idestrom M., Rubio C., Granath F., Finkel Y., and Hugot J. CARD15 mutations are rare in Swedish pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 40 (2005) 456-460
42. Cuthbert A., Fisher S., Mirza M., et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 122 (2002) 867-874
43. Lesage S., Zouali H., Cezard J., et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 70 (2002) 845-857
44. Ahmad T., Armuzzi A., Bunce M., et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 122 (2002) 854-866
45. Buning C., Genschel J., Buhner S., et al. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocaecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 19 (2004) 1073-1078
46. Buning C., Molnar T., Nagy F., et al. NOD2/CARD15 gene polymorphism in patients with inflammatory bowel disease: is Hungary different?. World J Gastroenterol 11 (2005) 407-411
47. Annese V., Lombardi G., Perri F., et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease-an IG-IBD study. Am J Gastroenterol 100 (2005) 84-92
48. Linde K., Boor P., Houwing-Duistermaat J., Kuipers E., Wilson J., and de Rooij F. CARD15 and Crohn's disease: healthy homozygous carriers of the 3020insC frameshift mutation. Am J Gastroenterol 98 (2003) 613-617
49. Mendoza J., Murillo L., Fernandez L., et al. Prevalence of mutations of the NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn disease. Scand J Gastroenterol 38 (2003) 1235-1240
50. Bonen D., Ogura Y., Nicolae D., et al. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 124 (2003) 140-146
51. Sugimura K., Taylor K., Lin Y., et al. A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews. Am J Hum Genet 72 (2003) 509-518
52. Economou M., Trikalinos T., Loizou K., Tsianos E., and Ioannidis J. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 99 (2004) 2393-2404
53. Brant S., Picco M., Achkar J., et al. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis 9 (2003) 281-289
54. Hampe J., Grebe J., Nikolaus S., et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 359 (2002) 1661-1665
55. Vavassori P., Borgiani P., D'Apice M., et al. 3020insC mutation within the NOD2 gene in Crohn's disease: frequency and association with clinical pattern in an Italian population. Dig Liver Dis 34 (2002) 153
56. Radlmayr M., Torok H., Martin K., and Folwaczny C. The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. Gastroenterology 122 (2002) 2091-2092
57. Abreu M., Taylor K., Lin Y., et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123 (2002) 679-688
58. Kugathasan S., Collins N., Maresso K., et al. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease. Clin Gastroenterol Hepatol 2 (2004) 1003-1009
59. Sun L., Roesler J., Rosen-Wolff A., et al. CARD15 genotype and phenotype analysis in 55 pediatric patients with crohn disease from Saxony, Germany. J Pediatr Gastroenterol Nutr 37 (2003) 492-497
60. Cosnes J., Cattan S., Blain A., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 8 (2002) 244-250
61. Mascheretti S., Hampe J., Croucher P., et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 12 (2002) 509-515
62. Vermeire S., Louis E., Rutgeerts P., et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 123 (2002) 106-111
63. Harton J., Linhoff M., Zhang J., and Ting J. Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains. J Immunol 169 (2002) 4088-4093
64. Miceli-Richard C., Lesage S., Rybojad M., et al. CARD15 mutations in Blau syndrome. Nat Genet 29 (2001) 19-20
65. Kanazawa N., Okafuji I., Kambe N., et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-(kappa)B activation: common genetic etiology with Blau syndrome. Blood 105 (2005) 1195-1197
66. Inohara N., Ogura Y., Chen F., Muto A., and Nunez G. Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J Biol Chem 276 (2001) 2551-2554
67. Girardin S., Boneca I., Viala J., et al. NOD2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278 (2003) 8869-8872
68. Inohara N., Ogura Y., Fontalba A., et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 278 (2003) 5509-5512
69. Watanabe T., Kitani A., Murray P., and Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nature Immunol 5 (2004) 800-808
70. Kobayashi K., Chamaillard M., Ogura Y., et al. NOD2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307 (2005) 731-734
71. Maeda S., Hsu L., Liu H., et al. NOD2 mutation in Crohn's disease potentiates NF-κB activity and IL-1β processing. Science 307 (2005) 734-738
72. Li J., Moran T., Swanson E., et al. Regulation of IL-8 and IL-1β expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet 13 (2004) 1715-1725
73. Netea M., Kullberg B., de Jong D., et al. NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 34 (2004) 2052-2059
74. van Heel D., Ghosh S., Butler M., et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 365 (2005) 1794-1796
75. Tanabe T., Chamaillard M., Ogura Y., et al. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J 23 (2004) 1587-1597
76. Vavricka S., Musch M., Chang J., et al. hPepT1 transports muramyl dipeptide, activating NF-κB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology 127 (2004) 1401-1409
77. Gutierrez O., Pipaon C., Inohara N., et al. Induction of NOD2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J Biol Chem 277 (2002) 41701-41705
78. Lala S., Ogura Y., Osborne C., et al. Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology 125 (2003) 47-57
79. Ayabe T., Satchell D., Wilson C., Parks W., Selsted M., and Ouellette A. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 1 (2000) 113-118
80. Schroder J. Epithelial antimicrobial peptides: innate local host response elements. Cell Mol Life Sci 56 (1999) 32-46
81. Salzman N., Ghosh D., Huttner K., Paterson Y., and Bevins C. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 422 (2003) 522-526
82. Wehkamp J., Salzman N., Porter E., et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 102 (2005) 18129-18134
83. Wehkamp J., Harder J., Weichenthal M., et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 53 (2004) 1658-1664
84. Wehkamp J., Harder J., Wehkamp K., et al. NFκB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 72 (2004) 5750-5758
85. Nuding S., Fellerman K., Wehkamp J., Mueller H., and Stange E. A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J Microbiol Meth (2005). published online Sept 22. DOI: 10.1016/j.mimet.2005.08.004
86. Hisamatsu T., Suzuki M., Reinecker H., Nadeau W., McCormick B., and Podolsky D. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124 (2003) 993-1000
87. Neurath M., Fuss I., Schurmann G., et al. Cytokine gene transcription by NF-κB family members in patients with inflammatory bowel disease. Ann N Y Acad Sci 859 (1998) 149-159
88. Chamaillard M., Philpott D., Girardin S., et al. Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci USA 100 (2003) 3455-3460
89. Chamaillard M., Girardin S., Viala J., and Philpott D. Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cell Microbiol 5 (2003) 581-592
90. Podolsky D. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
91. Pauleau A., and Murray P. Role of Nod2 in the response of macrophages to toll-like receptor agonists. Mol Cell Biol 23 (2003) 7531-7539
92. van Heel D., Ghosh S., Hunt K., et al. Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut 54 (2005) 1553-1557
93. Netea M., Ferwerda G., de Jong D., et al. Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol 174 (2005) 6518-6523
94. Barnich N., Hisamatsu T., Aguirre J., Xavier R., Reinecker H., and Podolsky D. GRIM-19 interacts with nucleotide oligomerization domain 2 and serves as downstream effector of anti-bacterial function in intestinal epithelial cells. J Biol Chem 280 (2005) 19021-19026
95. Abbott D., Wilkins A., Asara J., and Cantley L. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol 14 (2004) 2217-2227
96. Uehara A., Yang S., Fujimoto Y., et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol 7 (2005) 53-61
97. Yang S., Tamai R., Akashi S., et al. Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect Immun 69 (2001) 2045-2053
98. Traub S., Kubasch N., Morath S., et al. Structural requirements of synthetic muropeptides to synergize with lipopolysaccharide in cytokine induction. J Biol Chem 279 (2004) 8694-8700
99. Watanabe T., Kitani A., and Strober W. NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn's disease. Gut 54 (2005) 1515-1518
100. Strober W., Murray P., Kitani A., et al. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 6 (2006) 9-20
101. Stokkers P., Reitsma P., Tytgat G., and van Deventer S. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut 45 (1999) 395-401
102. Dechairo B., Dimon C., van Heel D., et al. Replication and extension studies of inflammatory bowel disease susceptibility regions confirm linkage to chromosome 6p (IBD3). Eur J Hum Genet 9 (2001) 627-633
103. Yang H., Plevy S., Taylor K., et al. Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses. Gut 44 (1999) 519-526
104. Fisher S., Hampe J., Macpherson A., et al. Sex stratification of an inflammatory bowel disease genome search shows male-specific linkage to the HLA region of chromosome 6. Eur J Hum Genet 10 (2002) 259-265
105. Rioux J., Silverberg M., Daly M., et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 66 (2000) 1863-1870
106. Roussomoustakaki M., Satsangi J., Welsh K., et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 112 (1997) 1845-1853
107. Yamamoto-Furusho J., Uscanga L., Vargas-Alarcon G., et al. Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis. Hum Immunol 64 (2003) 119-123
108. Trachtenberg E., Yang H., Hayes E., et al. HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish caucasian populations. Hum Immunol 61 (2000) 326-333
109. Silverberg M., Mirea L., Bull S., et al. A population- and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease. Inflamm Bowel Dis 9 (2003) 1-9
110. Orchard T., Thiyagaraja S., Welsh K., Wordsworth B., Hill Gaston J., and Jewell D. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 118 (2000) 274-278
111. Orchard T., Chua C., Ahmad T., Cheng H., Welsh K., and Jewell D. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 123 (2002) 714-718
112. Kildebo S., Nordgaard K., Aronsen O., Breckan R., Burhol P., and Jorde R. The incidence of ulcerative colitis in Northern Norway from 1983 to 1986. The Northern Norwegian Gastroenterology Society. Scand J Gastroenterol 25 (1990) 890-896
113. Rankin G., Watts H., Melnyk C., and Kelley Jr. M. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 77 (1979) 914-920
114. Ahmad T., Armuzzi A., Neville M., et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens 62 (2003) 527-535
115. Van Limbergen J., Russell R., Nimmo E., et al. Tumour necrosis factor α promoter polymorphisms influence disease phenotype and severity in childhood inflammatory bowel disease. Gut 55 suppl 2 (2006) A10
116. Negoro K., McGovern D., Kinouchi Y., et al. Analysis of the IBD5 locus and potential gene-gene interactions in Crohn's disease. Gut 52 (2003) 541-546
117. Armuzzi A., Ahmad T., Ling K., et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 52 (2003) 1133-1139
118. Giallourakis C., Stoll M., Miller K., et al. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and identification of a novel association with ulcerative colitis. Am J Hum Genet 73 (2003) 205-211
119. Mirza M., Fisher S., King K., et al. Genetic evidence for interaction of the 5q31 cytokine locus and the CARD15 gene in Crohn disease. Am J Hum Genet 72 (2003) 1018-1022
120. McGovern D., Van Heel D., Negoro K., Ahmad T., and Jewell D. Further evidence of IBD5/CARD15 (NOD2) epistasis in the susceptibility to ulcerative colitis. Am J Hum Genet 73 (2003) 1465-1466
121. Rioux J., Daly M., Silverberg M., et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet 29 (2001) 223-228
122. Goldstein D. Islands of linkage disequilibrium. Nat Genet 29 (2001) 109-111
123. Noble C., Nimmo E., Drummond H., et al. The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology 129 (2005) 1854-1864
124. Peltekova V., Wintle R., Rubin L., et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 36 (2004) 471-475
125. Daly M., Rioux J., Schaffner S., Hudson T., and Lander E. High-resolution haplotype structure in the human genome. Nat Genet 29 (2001) 229-232
126. Torok H., Glas J., Tonenchi L., et al. Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut 54 (2005) 1421-1427
127. Waller S., Tremelling M., Bredin F., Godfrey L., Howson J., and Parkes M. Evidence for association of OCTN genes and IBD5 with ulcerative colitis. Gut (2005). published online Dec 16. DOI:10.1136/gut.2005.084574
128. Vermeire S., Pierik M., Hiavaty T., et al. Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but no with susceptibility to IBD. Gastroenterology 129 (2005) 1845-1853
129. Russell R., Drummond H., Nimmo E., et al. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth parameters in early-onset inflammatory bowel disease. Gut (2006). published online Feb 9. DOI:10.1136/gut.2005.082107
130. Newman B., Gu X., Wintle R., et al. A risk haplotype in the solute carrier family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. Gastroenterology 128 (2005) 260-269
131. Satsangi J., Parkes M., Louis E., et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 14 (1996) 199-202
132. Panwala C., Jones J., and Viney J. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 161 (1998) 5733-5744
133. Schinkel A., Mayer U., Wagenaar E., et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94 (1997) 4028-4033
134. Wijnholds J., Evers R., van Leusden M., et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 3 (1997) 1275-1279
135. Moodie F., Lyons V., Satsangi J., and Seckl J. Effects of glucocorticoids on expression of P-glycoprotein and glucocorticoid receptor in the intestinal epithelium. Gastroenterology 126 (2004) A303
136. Mizoguchi E., Xavier R., Reinecker H., et al. Colonic epithelial functional phenotype varies with type and phase of experimental colitis. Gastroenterology 125 (2003) 148-161
137. Iizasa H., Genda N., Kitano T., et al. Altered expression and function of P-glycoprotein in dextran sodium sulfate-induced colitis in mice. J Pharm Sci 92 (2003) 569-576
138. Schwab M., Schaeffeler E., Marx C., et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124 (2003) 26-33
139. Croucher P., Mascheretti S., Foelsch U., Hampe J., and Schreiber S. Lack of association between the C3435T MDR1 gene polymorphism and inflammatory bowel disease in two independent Northern European populations. Gastroenterology 125 (2003) 1919-1920
140. Glas J., Torok H., Schiemann U., and Folwaczny C. MDR1 gene polymorphism in ulcerative colitis. Gastroenterology 126 (2004) 367
141. Brant S., Panhuysen C., Nicolae D., et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 73 (2003) 1282-1292
142. Potocnik U., Ferkolj I., Glavac D., and Dean M. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun 5 (2004) 530-539
143. Ho G., Nimmo E., Tenesa A., et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 128 (2005) 288-296
144. Ho G., Soranzo N., Tenesa A., Goldstein D., and Satsangi J. The ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet 15 (2006) 797-805
145. Thiebaut F., Tsuruo T., Hamada H., Gottesman M., Pastan I., and Willingham M. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84 (1987) 7735-7738
146. Ho G., Moodie F., and Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?. Gut 52 (2003) 759-766
147. Langmann T., Moehle C., Mauerer R., et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 127 (2004) 26-40
148. Stoll M., Corneliussen B., Costello C., et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 36 (2004) 476-480
149. Peeters M., Geypens B., Claus D., et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 113 (1997) 802-807
150. Daly M., Pearce A., Farwell L., et al. Association of DLG5 R30Q variant with inflammatory bowel disease. Eur J Hum Gen 13 (2005) 835-839
151. Noble C., Nimmo E., Drummond H., Smith L., Arnott I., and Satsangi J. DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population. Gut 54 (2005) 1416-1420
152. Newman W., Gu X., Wintle R., et al. DLG5 variants contribute to Crohn's disease risk in a Canadian population. Hum Mutat (2006). published online Jan 31. DOI 10.1002/humu.20301
153. Cummings J., Herrlinger K., Ahmad T., and Jewell D. Genotype-phenotype analyses of the IBD susceptibility gene DLG5. Gut 54 (2005) 360
154. Russell R., Drummond H., Nimmo E., et al. The Dlg 5-113a mutation is associated with susceptibility to early onset inflammatory bowel disease and demonstrates a complex genotype phenotype relationship. J Pediatr Gastroenterol Nutr 40 (2005) 641-642
155. Trinh T., and Rioux J. The promise and perils of interpreting genetic associations in Crohn's disease. Gut 54 (2005) 1354-1357
156. Friedrichs F., Brescianini S., Annere V., et al. Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implications of an association with Crohn's disease in men. Hum Genet (2006). published online Jan 31. DOI: 10.1007/s00439-006-0133-1
157. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., and Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118 (2004) 229-241
158. Kopp E., and Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol 15 (2003) 396-401
159. Cario E., and Podolsky D. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 68 (2000) 7010-7017
160. Arbour N., Lorenz E., Schutte B., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25 (2000) 187-191
161. Franchimont D., Vermeire S., El Housni H., et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53 (2004) 987-992
162. Ouburg S., Mallant-Hent R., Crusius J., et al. The toll-like receptor 4 (TLR4) Asp299Gly polymorphism is associated with colonic localisation of Crohn's disease without a major role for the Saccharomyces cerevisiae mannan-LBP-CD14-TLR4 pathway. Gut 54 (2005) 439-440
163. Gazouli M., Mantzaris G., Kotsinas A., et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 11 (2005) 681-685
164. Torok H., Glas J., Tonenchi L., Mussack T., and Folwaczny C. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 112 (2004) 85-91
165. Lakatos P., Lakatos L., Szalay F., et al. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J Gastroenterol 11 (2005) 1489-1495
166. Oostenbrug L., Drenth J., de Jong D., et al. Association between toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 567-575
167. Fort M., Mozaffarian A., Stover A., et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 174 (2005) 6416-6423
168. Hayashi F., Smith K., Ozinsky A., et al. The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature 410 (2001) 1099-1103
169. Winstanley C., and Morgan J. The bacterial flagellin gene as a biomarker for detection, population genetics and epidemiological analysis. Microbiology 143 (1997) 3071-3084
170. Lodes M., Cong Y., Elson C., et al. Bacterial flagellin is a dominant antigen in Crohn disease. Infect Immun 113 (2004) 1296-1306
171. Gerwitz A., Vijay-Kumar M., Swanson E., Duerr R., Brant S., and Cho J. Common dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and provides protection from Crohn's disease. Gastroenterology 128 suppl 2 (2005) A388
172. Inohara N., Koseki T., Lin J., et al. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. J Biol Chem 275 (2000) 27823-27831
173. Chamaillard M., Hashimoto M., Horie Y., et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 4 (2003) 702-707
174. Kim J., Lee S., and Kagnoff M. NOD1 is an essential signal transducer in intestinal epithelial cells infected with bacteria that avoid recognition by toll-like receptors. Infect Immun 72 (2004) 1487-1495
175. Zouali H., Lesage S., Merlin F., et al. CARD4/NOD1 is not involved in inflammatory bowel disease. Gut 52 (2003) 71-74
176. McGovern D., Hysi P., Ahmad T., et al. Association between a complex insertion/deletion polymorphism in NOD1(CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet 14 (2005) 1245-1250
177. Hysi P., Kabesch M., Moffatt M., et al. NOD1 variation, immunoglobulin E and asthma. Hum Mol Genet 14 (2005) 935-941
178. Van Heel D., Ghosh S., Butler M., et al. Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol 35 (2005) 2471-2476
179. Fritz J., Girardin S., Fitting C., et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol 35 (2005) 2459-2470
180. Kobayashi K., Inohara N., Hernandez L., et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416 (2002) 194-199
181. Netea M., Ferwerda G., de Jong D., et al. The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2- but also Nod1-activating peptidoglycan agonists. J Biol Chem 280 (2005) 35859-35867
182. Crawford N., Uthoff S., Eichenberger M., et al. Characterization of genotype-phenotype correlations show that the IBD2 susceptibility locus is associated with colonic Crohn's disease and ulcerative colitis. Gastroenterology 124 (2003) A48
183. Vermeire S., Rutgeerts P., Van Steen K., et al. Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis. Gut 53 (2004) 980-986
184. Duerr R., Barmada M., Zhang L., Pfutzer R., and Weeks D. High-density genome scan in Crohn disease shows confirmed linkage to chromosome 14q11-12. Am J Hum Genet 66 (2000) 1857-1862
185. Pierik M., Yang H., Barmada M., et al. The IBD international genetics consortium provides further evidence for linkage to IBD4 and shows gene-environment interaction. Inflamm Bowel Dis 11 (2005) 1-7
186. Silverberg M., Satsangi J., Ahmad T., et al. Towards an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 suppl A (2005) 5-36
187. Trinh T., and Rioux J. Understanding association and causality in the genetic studies of inflammatory bowel disease. Gastroenterology 129 (2005) 2106-2109
188. Tenesa A., Noble C., Satsangi J., et al. Association of DLG5 and inflammatory bowel disease across populations. Eur Jnl Hum Genet (2006). published online Jan 4. DOI:10.1038/sj.ejhg.5201516